Midazolam. A review of its pharmacological properties and therapeutic use

J. W. Dundee, N. J. Halliday, K. W. Harper, R. N. Brogden

Research output: Contribution to journalArticle

275 Citations (Scopus)

Abstract

Midazolam is a short-acting water-soluble benzodiazepine (at pH < 4), a member of a new class of imidazobenzodiazepine derivatives. At physiological pH the drug becomes much more lipid soluble. Water solubility minimises pain on injection and venous thrombosis compared with diazepam administered in organic solvent. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. To date it has been used mostly by the intravenous route, for sedation in dentistry and endoscopic procedures and as an adjunct to local anaesthetic techniques. It has proved less reliable than thiopentone, but preferable to diazepam, as an intravenous induction agent and is unlikely to replace the other well established drugs. However, due to the cardiorespiratory stability following its administration, midazolam is useful for anaesthetic induction in poor-risk, elderly and cardiac patients. The short elimination half-life (1.5-3.5 h) and the absence of clinically important long acting metabolites make midazolam suitable for long term infusion as a sedative and amnestic for intensive care, but clinical trials have yet to be completed. Thus, a combination of properties make midazolam a useful addition to the benzo-diazepine group.

Original languageEnglish
Pages (from-to)519-543
Number of pages25
JournalDrugs
Volume28
Issue number6
StatePublished - Dec 1 1984
Externally publishedYes

Fingerprint

Midazolam
Therapeutic Uses
Pharmacology
Diazepam
Hypnotics and Sedatives
Pharmaceutical Preparations
Dentistry
Thiopental
Water
Anti-Anxiety Agents
Critical Care
Metabolites
Local Anesthetics
Benzodiazepines
Venous Thrombosis
Solubility
Organic solvents
Half-Life
Anesthetics
Clinical Trials

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Dundee, J. W., Halliday, N. J., Harper, K. W., & Brogden, R. N. (1984). Midazolam. A review of its pharmacological properties and therapeutic use. Drugs, 28(6), 519-543.

Midazolam. A review of its pharmacological properties and therapeutic use. / Dundee, J. W.; Halliday, N. J.; Harper, K. W.; Brogden, R. N.

In: Drugs, Vol. 28, No. 6, 01.12.1984, p. 519-543.

Research output: Contribution to journalArticle

Dundee, JW, Halliday, NJ, Harper, KW & Brogden, RN 1984, 'Midazolam. A review of its pharmacological properties and therapeutic use', Drugs, vol. 28, no. 6, pp. 519-543.
Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam. A review of its pharmacological properties and therapeutic use. Drugs. 1984 Dec 1;28(6):519-543.
Dundee, J. W. ; Halliday, N. J. ; Harper, K. W. ; Brogden, R. N. / Midazolam. A review of its pharmacological properties and therapeutic use. In: Drugs. 1984 ; Vol. 28, No. 6. pp. 519-543.
@article{1bcf7519b4584ff488748873b3f23d7a,
title = "Midazolam. A review of its pharmacological properties and therapeutic use",
abstract = "Midazolam is a short-acting water-soluble benzodiazepine (at pH < 4), a member of a new class of imidazobenzodiazepine derivatives. At physiological pH the drug becomes much more lipid soluble. Water solubility minimises pain on injection and venous thrombosis compared with diazepam administered in organic solvent. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. To date it has been used mostly by the intravenous route, for sedation in dentistry and endoscopic procedures and as an adjunct to local anaesthetic techniques. It has proved less reliable than thiopentone, but preferable to diazepam, as an intravenous induction agent and is unlikely to replace the other well established drugs. However, due to the cardiorespiratory stability following its administration, midazolam is useful for anaesthetic induction in poor-risk, elderly and cardiac patients. The short elimination half-life (1.5-3.5 h) and the absence of clinically important long acting metabolites make midazolam suitable for long term infusion as a sedative and amnestic for intensive care, but clinical trials have yet to be completed. Thus, a combination of properties make midazolam a useful addition to the benzo-diazepine group.",
author = "Dundee, {J. W.} and Halliday, {N. J.} and Harper, {K. W.} and Brogden, {R. N.}",
year = "1984",
month = "12",
day = "1",
language = "English",
volume = "28",
pages = "519--543",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Midazolam. A review of its pharmacological properties and therapeutic use

AU - Dundee, J. W.

AU - Halliday, N. J.

AU - Harper, K. W.

AU - Brogden, R. N.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - Midazolam is a short-acting water-soluble benzodiazepine (at pH < 4), a member of a new class of imidazobenzodiazepine derivatives. At physiological pH the drug becomes much more lipid soluble. Water solubility minimises pain on injection and venous thrombosis compared with diazepam administered in organic solvent. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. To date it has been used mostly by the intravenous route, for sedation in dentistry and endoscopic procedures and as an adjunct to local anaesthetic techniques. It has proved less reliable than thiopentone, but preferable to diazepam, as an intravenous induction agent and is unlikely to replace the other well established drugs. However, due to the cardiorespiratory stability following its administration, midazolam is useful for anaesthetic induction in poor-risk, elderly and cardiac patients. The short elimination half-life (1.5-3.5 h) and the absence of clinically important long acting metabolites make midazolam suitable for long term infusion as a sedative and amnestic for intensive care, but clinical trials have yet to be completed. Thus, a combination of properties make midazolam a useful addition to the benzo-diazepine group.

AB - Midazolam is a short-acting water-soluble benzodiazepine (at pH < 4), a member of a new class of imidazobenzodiazepine derivatives. At physiological pH the drug becomes much more lipid soluble. Water solubility minimises pain on injection and venous thrombosis compared with diazepam administered in organic solvent. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. To date it has been used mostly by the intravenous route, for sedation in dentistry and endoscopic procedures and as an adjunct to local anaesthetic techniques. It has proved less reliable than thiopentone, but preferable to diazepam, as an intravenous induction agent and is unlikely to replace the other well established drugs. However, due to the cardiorespiratory stability following its administration, midazolam is useful for anaesthetic induction in poor-risk, elderly and cardiac patients. The short elimination half-life (1.5-3.5 h) and the absence of clinically important long acting metabolites make midazolam suitable for long term infusion as a sedative and amnestic for intensive care, but clinical trials have yet to be completed. Thus, a combination of properties make midazolam a useful addition to the benzo-diazepine group.

UR - http://www.scopus.com/inward/record.url?scp=0021743129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021743129&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 519

EP - 543

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 6

ER -